You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameClevidipine
Accession NumberDB04920
TypeSmall Molecule
GroupsApproved
DescriptionClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Structure
Thumb
Synonyms
Clevidipine butyrate
External Identifiers
  • H-324/38
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CleviprexEmulsion.5 mg/mLIntravenousThe Medicines Company2008-09-15Not applicableUs
CleviprexEmulsion0.5 mgIntravenousChiesi Farmaceutici S.P.A.Not applicableNot applicableCanada
CleviprexEmulsion.5 mg/mLIntravenousFresenius Kabi Austria Gmb H2008-09-15Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII19O2GP3B7Q
CAS number167221-71-8
WeightAverage: 456.316
Monoisotopic: 455.090242887
Chemical FormulaC21H23Cl2NO6
InChI KeyKPBZROQVTHLCDU-UHFFFAOYSA-N
InChI
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
IUPAC Name
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
SMILES
CCCC(=O)OCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(Cl)=C1Cl)C(=O)OC
Pharmacology
IndicationFor the treatment of hypertension.
Structured Indications
PharmacodynamicsClevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output.
Mechanism of actionPossibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue.
TargetKindPharmacological actionActionsOrganismUniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1FProteinunknownNot AvailableHumanO60840 details
Voltage-dependent L-type calcium channel subunit alpha-1SProteinunknownNot AvailableHumanQ13698 details
Voltage-dependent L-type calcium channel subunit alpha-1DProteinunknownNot AvailableHumanQ01668 details
Voltage-dependent L-type calcium channel subunit alpha-1CProteinunknownNot AvailableHumanQ13936 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding>99.5%
Metabolism

Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Route of eliminationurine 63-74%, feces 7-22%
Half life1 minute
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Clevidipine.Experimental
2-mercaptobenzothiazoleThe risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Clevidipine.Vet Approved
AbirateroneThe serum concentration of Clevidipine can be increased when it is combined with Abiraterone.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Clevidipine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Acetazolamide.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Clevidipine.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Clevidipine.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Clevidipine is combined with Aliskiren.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Clevidipine.Approved
AmiodaroneThe metabolism of Clevidipine can be decreased when combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Clevidipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Clevidipine.Approved, Illicit
AmorolfineThe risk or severity of adverse effects can be increased when Amorolfine is combined with Clevidipine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Clevidipine.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Clevidipine.Approved
AN2690The risk or severity of adverse effects can be increased when AN2690 is combined with Clevidipine.Investigational
AnidulafunginThe risk or severity of adverse effects can be increased when Anidulafungin is combined with Clevidipine.Approved, Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Clevidipine.Approved
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Clevidipine.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Clevidipine is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe risk or severity of adverse effects can be increased when Artemether is combined with Clevidipine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Clevidipine.Approved
AtomoxetineThe metabolism of Clevidipine can be decreased when combined with Atomoxetine.Approved
AtosibanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Atosiban.Approved
Atracurium besylateClevidipine may increase the neuromuscular blocking activities of Atracurium besylate.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Azilsartan medoxomil.Approved
AzithromycinThe metabolism of Clevidipine can be decreased when combined with Azithromycin.Approved
Bafilomycin A1The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Clevidipine.Experimental
BarbexacloneBarbexaclone may increase the hypotensive activities of Clevidipine.Experimental
BarbitalBarbital may increase the hypotensive activities of Clevidipine.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Clevidipine.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Clevidipine.Approved
Benzoic AcidThe risk or severity of adverse effects can be increased when Benzoic Acid is combined with Clevidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Clevidipine.Approved
BifonazoleThe risk or severity of adverse effects can be increased when Bifonazole is combined with Clevidipine.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Clevidipine.Approved
BortezomibThe metabolism of Clevidipine can be decreased when combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Clevidipine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Clevidipine.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bromocriptine.Approved, Investigational
BucindololBucindolol may increase the hypotensive activities of Clevidipine.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Clevidipine.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Bupivacaine.Approved, Investigational
BupropionThe metabolism of Clevidipine can be decreased when combined with Bupropion.Approved
ButenafineThe risk or severity of adverse effects can be increased when Butenafine is combined with Clevidipine.Approved
ButoconazoleThe risk or severity of adverse effects can be increased when Butoconazole is combined with Clevidipine.Approved
CaffeineThe metabolism of Clevidipine can be decreased when combined with Caffeine.Approved
CalciumThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium.Nutraceutical
Calcium AcetateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Acetate.Approved
Calcium carbonateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium carbonate.Approved
Calcium ChlorideThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Chloride.Approved
Calcium citrateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium citrate.Approved
Calcium glubionateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Clevidipine.Approved
CandicidinThe risk or severity of adverse effects can be increased when Candicidin is combined with Clevidipine.Withdrawn
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Clevidipine.Approved
CarbamazepineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Carbetocin.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Clevidipine.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Clevidipine.Approved, Investigational
CaspofunginThe risk or severity of adverse effects can be increased when Caspofungin is combined with Clevidipine.Approved
CelecoxibThe metabolism of Clevidipine can be decreased when combined with Celecoxib.Approved, Investigational
CeruleninThe risk or severity of adverse effects can be increased when Cerulenin is combined with Clevidipine.Approved
ChloroquineThe metabolism of Clevidipine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.Approved, Vet Approved
ChloroxineThe risk or severity of adverse effects can be increased when Chloroxine is combined with Clevidipine.Approved
ChlorpromazineThe metabolism of Clevidipine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Clevidipine.Approved
CholecalciferolThe metabolism of Clevidipine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe risk or severity of adverse effects can be increased when Ciclopirox is combined with Clevidipine.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Clevidipine.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Cilnidipine.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Clevidipine.Approved
CimetidineThe serum concentration of Clevidipine can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Clevidipine can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Clevidipine can be decreased when combined with Citalopram.Approved
ClemastineThe metabolism of Clevidipine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Clevidipine can be decreased when combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Clofarabine.Approved, Investigational
ClomipramineThe metabolism of Clevidipine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Clevidipine.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Clevidipine.Approved, Nutraceutical
ClotrimazoleThe risk or severity of adverse effects can be increased when Clotrimazole is combined with Clevidipine.Approved, Vet Approved
ClozapineThe metabolism of Clevidipine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Clevidipine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Clevidipine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Conivaptan.Approved, Investigational
CordycepinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Clevidipine.Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Clevidipine.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Clevidipine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Clevidipine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Clevidipine.Investigational
DarifenacinThe metabolism of Clevidipine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Clevidipine can be increased when it is combined with Darunavir.Approved
Decanoic AcidThe risk or severity of adverse effects can be increased when Decanoic Acid is combined with Clevidipine.Experimental
DeferasiroxThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Clevidipine can be decreased when combined with Delavirdine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Desflurane.Approved
DesipramineThe metabolism of Clevidipine can be decreased when combined with Desipramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Clevidipine.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Clevidipine.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Clevidipine.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Clevidipine is combined with Dinutuximab.Approved
DiphenhydramineThe metabolism of Clevidipine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Clevidipine.Approved
DisulfiramThe metabolism of Clevidipine can be decreased when combined with Disulfiram.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Clevidipine.Approved
DronedaroneThe metabolism of Clevidipine can be decreased when combined with Dronedarone.Approved
DuloxetineClevidipine may increase the orthostatic hypotensive activities of Duloxetine.Approved
EconazoleThe risk or severity of adverse effects can be increased when Econazole is combined with Clevidipine.Approved
EfavirenzThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe risk or severity of adverse effects can be increased when Efinaconazole is combined with Clevidipine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Efonidipine.Approved
EliglustatThe metabolism of Clevidipine can be decreased when combined with Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Clevidipine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Clevidipine is combined with Enalaprilat.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Clevidipine.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Clevidipine is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Clevidipine.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Clevidipine.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Clevidipine is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Fimasartan.Approved
FluconazoleThe serum concentration of Clevidipine can be increased when it is combined with Fluconazole.Approved
FlucytosineThe risk or severity of adverse effects can be increased when Flucytosine is combined with Clevidipine.Approved
FluoxetineThe metabolism of Clevidipine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Clevidipine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Clevidipine.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Clevidipine.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Clevidipine.Approved, Vet Approved
GlyphosateThe risk or severity of adverse effects can be increased when Glyphosate is combined with Clevidipine.Experimental
GriseofulvinThe risk or severity of adverse effects can be increased when Griseofulvin is combined with Clevidipine.Approved, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.Approved, Investigational
HaloperidolThe metabolism of Clevidipine can be decreased when combined with Haloperidol.Approved
HaloproginThe risk or severity of adverse effects can be increased when Haloprogin is combined with Clevidipine.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Halothane.Approved, Vet Approved
HexetidineThe risk or severity of adverse effects can be increased when Hexetidine is combined with Clevidipine.Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Clevidipine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Clevidipine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Clevidipine.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Hydroflumethiazide.Approved
IloprostThe risk or severity of adverse effects can be increased when Clevidipine is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Imidapril.Investigational
ImipramineThe metabolism of Clevidipine can be decreased when combined with Imipramine.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Clevidipine.Approved
IndinavirThe metabolism of Clevidipine can be decreased when combined with Indinavir.Approved
IndoraminIndoramin may increase the hypotensive activities of Clevidipine.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Clevidipine.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isocarboxazid.Approved
IsoconazoleThe risk or severity of adverse effects can be increased when Isoconazole is combined with Clevidipine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Clevidipine can be decreased when combined with Isoniazid.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Clevidipine.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Clevidipine.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Clevidipine.Approved
ItraconazoleThe risk or severity of adverse effects can be increased when Itraconazole is combined with Clevidipine.Approved, Investigational
KetoconazoleThe risk or severity of adverse effects can be increased when Ketoconazole is combined with Clevidipine.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Clevidipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lacidipine.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Clevidipine.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Levobupivacaine.Approved
LevodopaClevidipine may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Clevidipine is combined with Levosimendan.Approved, Investigational
LidocaineThe metabolism of Clevidipine can be decreased when combined with Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Clevidipine.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Clevidipine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Clevidipine can be decreased when combined with Lorcaserin.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Clevidipine.Approved
LumefantrineThe metabolism of Clevidipine can be decreased when combined with Lumefantrine.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium hydroxide.Approved
Magnesium oxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium salicylate.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Clevidipine is combined with Magnesium Sulfate.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Clevidipine.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Clevidipine.Approved
MelatoninMelatonin may decrease the antihypertensive activities of Clevidipine.Approved, Nutraceutical, Vet Approved
MethadoneThe metabolism of Clevidipine can be decreased when combined with Methadone.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Clevidipine.Approved
MethohexitalMethohexital may increase the hypotensive activities of Clevidipine.Approved
MethotrimeprazineThe metabolism of Clevidipine can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Clevidipine.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Clevidipine.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Clevidipine.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Clevidipine.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Clevidipine.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clevidipine.Approved, Investigational
MevastatinThe risk or severity of adverse effects can be increased when Mevastatin is combined with Clevidipine.Experimental
MexiletineThe metabolism of Clevidipine can be decreased when combined with Mexiletine.Approved
MicafunginThe risk or severity of adverse effects can be increased when Micafungin is combined with Clevidipine.Approved, Investigational
MiconazoleThe risk or severity of adverse effects can be increased when Miconazole is combined with Clevidipine.Approved, Investigational, Vet Approved
MiltefosineThe risk or severity of adverse effects can be increased when Miltefosine is combined with Clevidipine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Clevidipine.Approved
MirabegronThe metabolism of Clevidipine can be decreased when combined with Mirabegron.Approved
MivacuriumClevidipine may increase the neuromuscular blocking activities of Mivacurium.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Clevidipine.Approved
MonensinThe risk or severity of adverse effects can be increased when Monensin is combined with Clevidipine.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Moxonidine.Approved
MyxothiazolThe risk or severity of adverse effects can be increased when Myxothiazol is combined with Clevidipine.Experimental
NabiloneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Clevidipine.Approved
NafcillinThe metabolism of Clevidipine can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Clevidipine.Approved
NatamycinThe risk or severity of adverse effects can be increased when Natamycin is combined with Clevidipine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Clevidipine.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Clevidipine.Approved, Investigational
NevirapineThe metabolism of Clevidipine can be decreased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Clevidipine.Approved
NicorandilNicorandil may increase the hypotensive activities of Clevidipine.Approved
NicotineThe metabolism of Clevidipine can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Clevidipine.Approved
NilotinibThe metabolism of Clevidipine can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Clevidipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Clevidipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Clevidipine.Approved, Investigational
NitroprussideClevidipine may increase the hypotensive activities of Nitroprusside.Approved
NitroxolineThe risk or severity of adverse effects can be increased when Nitroxoline is combined with Clevidipine.Approved
NystatinThe risk or severity of adverse effects can be increased when Nystatin is combined with Clevidipine.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Clevidipine is combined with Obinutuzumab.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Clevidipine.Approved, Investigational
OsimertinibThe serum concentration of Clevidipine can be decreased when it is combined with Osimertinib.Approved
OxiconazoleThe risk or severity of adverse effects can be increased when Oxiconazole is combined with Clevidipine.Approved
OxprenololThe risk or severity of adverse effects can be increased when Clevidipine is combined with Oxprenolol.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Clevidipine is combined with Paclitaxel.Approved, Vet Approved
pafuramidineThe risk or severity of adverse effects can be increased when pafuramidine is combined with Clevidipine.Investigational
PanobinostatThe serum concentration of Clevidipine can be increased when it is combined with Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Clevidipine.Approved
ParoxetineThe metabolism of Clevidipine can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Clevidipine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Clevidipine.Approved, Investigational
PentamidineThe risk or severity of adverse effects can be increased when Pentamidine is combined with Clevidipine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Phenelzine.Approved
PhenobarbitalThe metabolism of Clevidipine can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Phenoxybenzamine.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Phentolamine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Clevidipine.Approved, Vet Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Clevidipine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pipamperone.Approved
PosaconazoleThe risk or severity of adverse effects can be increased when Posaconazole is combined with Clevidipine.Approved, Investigational, Vet Approved
PramipexoleThe risk or severity of adverse effects can be increased when Clevidipine is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Clevidipine.Approved
PrimidoneThe metabolism of Clevidipine can be increased when combined with Primidone.Approved, Vet Approved
PromazineThe metabolism of Clevidipine can be decreased when combined with Promazine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Clevidipine is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Clevidipine.Approved, Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Clevidipine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Clevidipine.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Clevidipine.Approved
QuinineThe metabolism of Clevidipine can be decreased when combined with Quinine.Approved
RadicicolThe risk or severity of adverse effects can be increased when Radicicol is combined with Clevidipine.Experimental
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Clevidipine.Approved
RanolazineThe metabolism of Clevidipine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumClevidipine may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Remifentanil.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Clevidipine.Approved
RifabutinThe serum concentration of Clevidipine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe metabolism of Clevidipine can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Clevidipine can be decreased when it is combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Clevidipine is combined with Riociguat.Approved
RisperidoneClevidipine may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe metabolism of Clevidipine can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe metabolism of Clevidipine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Clevidipine can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sacubitril.Approved
Salicylhydroxamic AcidThe risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Clevidipine.Experimental
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Clevidipine.Approved, Vet Approved
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Clevidipine.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Selegiline.Approved, Investigational, Vet Approved
SertaconazoleThe risk or severity of adverse effects can be increased when Sertaconazole is combined with Clevidipine.Approved
SertralineThe metabolism of Clevidipine can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sevoflurane.Approved, Vet Approved
SilodosinSilodosin may increase the hypotensive activities of Clevidipine.Approved
SimeprevirThe metabolism of Clevidipine can be decreased when combined with Simeprevir.Approved
SinefunginThe risk or severity of adverse effects can be increased when Sinefungin is combined with Clevidipine.Experimental
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Clevidipine.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Clevidipine.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.Approved
StiripentolThe metabolism of Clevidipine can be decreased when combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Clevidipine is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sufentanil.Approved, Investigational
SulconazoleThe risk or severity of adverse effects can be increased when Sulconazole is combined with Clevidipine.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Clevidipine.Approved, Investigational
TamsulosinTamsulosin may increase the hypotensive activities of Clevidipine.Approved, Investigational
TavaboroleThe risk or severity of adverse effects can be increased when Tavaborole is combined with Clevidipine.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Clevidipine.Approved, Investigational
TenofovirThe metabolism of Clevidipine can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Clevidipine.Approved
TerbinafineThe metabolism of Clevidipine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe risk or severity of adverse effects can be increased when Terconazole is combined with Clevidipine.Approved
TeriflunomideThe serum concentration of Clevidipine can be decreased when it is combined with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Clevidipine is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Clevidipine can be decreased when combined with Theophylline.Approved
ThiamylalThiamylal may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Clevidipine.Approved, Vet Approved
ThioridazineThe metabolism of Clevidipine can be decreased when combined with Thioridazine.Approved
ThymolThe risk or severity of adverse effects can be increased when Thymol is combined with Clevidipine.Approved
TiclopidineThe metabolism of Clevidipine can be decreased when combined with Ticlopidine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Clevidipine.Approved
TioconazoleThe risk or severity of adverse effects can be increased when Tioconazole is combined with Clevidipine.Approved
TipranavirThe metabolism of Clevidipine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Clevidipine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Clevidipine is combined with Tolcapone.Approved, Withdrawn
TolnaftateThe risk or severity of adverse effects can be increased when Tolnaftate is combined with Clevidipine.Approved, Vet Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Clevidipine.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Clevidipine.Approved
TranylcypromineThe metabolism of Clevidipine can be decreased when combined with Tranylcypromine.Approved
TretinoinThe risk or severity of adverse effects can be increased when Clevidipine is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Clevidipine.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Clevidipine.Experimental
TrimetrexateThe risk or severity of adverse effects can be increased when Trimetrexate is combined with Clevidipine.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Clevidipine.Approved, Investigational
VemurafenibThe serum concentration of Clevidipine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Clevidipine can be decreased when combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Clevidipine.Approved
VoriconazoleThe risk or severity of adverse effects can be increased when Voriconazole is combined with Clevidipine.Approved, Investigational
ZiprasidoneThe metabolism of Clevidipine can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Grapefruit Juice
References
Synthesis ReferenceNot Available
General References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
  2. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
  3. Wang QD, Segawa D, Ericsson H, Sjoquist PO, Johansson L, Ryden L: Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I. J Cardiovasc Pharmacol. 2002 Aug;40(2):228-34. [PubMed:12131552 ]
  4. Stephens CT, Jandhyala BS: Effects of fenoldopam, a dopamine D-1 agonist, and clevidipine, a calcium channel antagonist, in acute renal failure in anesthetized rats. Clin Exp Hypertens. 2002 May;24(4):301-13. [PubMed:12069360 ]
External Links
ATC CodesC08CA16
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (381 KB)
MSDSDownload (568 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9887
Blood Brain Barrier-0.5892
Caco-2 permeable+0.6566
P-glycoprotein substrateSubstrate0.5787
P-glycoprotein inhibitor IInhibitor0.8948
P-glycoprotein inhibitor IINon-inhibitor0.6827
Renal organic cation transporterNon-inhibitor0.8312
CYP450 2C9 substrateNon-substrate0.8879
CYP450 2D6 substrateNon-substrate0.8693
CYP450 3A4 substrateSubstrate0.693
CYP450 1A2 substrateInhibitor0.6871
CYP450 2C9 inhibitorInhibitor0.6818
CYP450 2D6 inhibitorNon-inhibitor0.8455
CYP450 2C19 inhibitorInhibitor0.7456
CYP450 3A4 inhibitorInhibitor0.9187
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.9098
Ames testNon AMES toxic0.7527
CarcinogenicityNon-carcinogens0.8407
BiodegradationNot ready biodegradable0.9403
Rat acute toxicity2.6248 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7841
hERG inhibition (predictor II)Non-inhibitor0.8148
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
EmulsionIntravenous.5 mg/mL
EmulsionIntravenous0.5 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5739152 No1995-04-142015-04-14Us
US5856346 No2001-01-052021-01-05Us
US8658676 No2011-10-102031-10-10Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00267 mg/mLALOGPS
logP4.98ALOGPS
logP4.09ChemAxon
logS-5.2ALOGPS
pKa (Strongest Basic)5.31ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area90.93 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity113.93 m3·mol-1ChemAxon
Polarizability45.12 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyridines and derivatives
Sub ClassHydropyridines
Direct ParentDihydropyridinecarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tricarboxylic acid or derivatives
  • Dihydropyridinecarboxylic acid derivative
  • 1,2-dichlorobenzene
  • Acylal
  • Halobenzene
  • Fatty acid ester
  • Chlorobenzene
  • Fatty acyl
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Vinylogous amide
  • Alpha,beta-unsaturated carboxylic ester
  • Enoate ester
  • Methyl ester
  • Carboxylic acid ester
  • Azacycle
  • Enamine
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1F
Uniprot ID:
O60840
Molecular Weight:
220675.9 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1S gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1S
Uniprot ID:
Q13698
Molecular Weight:
212348.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity involved sa node cell action potential
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1D gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1D
Uniprot ID:
Q01668
Molecular Weight:
245138.75 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Voltage-gated calcium channel activity
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1C gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belon...
Gene Name:
CACNA1C
Uniprot ID:
Q13936
Molecular Weight:
248974.1 Da
References
  1. Nordlander M, Sjoquist PO, Ericsson H, Ryden L: Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc Drug Rev. 2004 Fall;22(3):227-50. [PubMed:15492770 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhang JG, Dehal SS, Ho T, Johnson J, Chandler C, Blanchard AP, Clark RJ Jr, Crespi CL, Stresser DM, Wong J: Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81. Drug Metab Dispos. 2006 May;34(5):734-7. Epub 2006 Feb 24. [PubMed:16501008 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Ericsson H, Tholander B, Regardh CG: In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man. Eur J Pharm Sci. 1999 Apr;8(1):29-37. [PubMed:10072476 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 16:23 / Updated on December 04, 2016 02:44